Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6420
    -0.0005 (-0.08%)
     
  • OIL

    83.71
    +0.98 (+1.18%)
     
  • GOLD

    2,404.90
    +6.90 (+0.29%)
     
  • Bitcoin AUD

    100,898.85
    +5,484.27 (+5.75%)
     
  • CMC Crypto 200

    1,332.92
    +20.30 (+1.55%)
     
  • AUD/EUR

    0.6025
    -0.0006 (-0.10%)
     
  • AUD/NZD

    1.0885
    +0.0010 (+0.09%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    0.00 (0.00%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,236.64
    -149.23 (-0.91%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Here's Why This Dividend King Is a Buy

Here's Why This Dividend King Is a Buy

Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.